Last quarter, a founder called me in a mild panic. She'd been offered advisor equity, her co-founder wanted to issue shares to a key hire, and a potential investor asked for her pre-money valuation, all in the same week. She had zero revenue and no idea how to put a number on the company. That's the reality for most early-stage founders: the need for a valuation shows up before the data to support one.
Pre-revenue valuation isn't about precision. It's about building a defensible range that both sides can negotiate from. The method you choose matters less than understanding what each one actually measures and where it breaks down. Every valuation method carries assumptions, and the trick is matching the method to the company's lifecycle stage, because a Phase 2 company building its first product needs a completely different approach than a Phase 4 company scaling revenue.
When You Actually Need a Valuation
Before you pick a method, it's worth asking why you need a number in the first place. The "when" gives context to the "how," and most founders don't realize how many situations force the question.
Fundraising. The obvious one. Any priced equity round requires a pre-money valuation. Even SAFEs and convertible notes reference a valuation cap, which is a proxy for the same thing. You can't sell a piece of the company without agreeing on what the whole company is worth.
Equity grants to employees and advisors. Every time you issue stock options or restricted stock, you're implicitly putting a price on the company. Early hires and advisors negotiate based on that number, and getting it wrong in either direction creates problems. Too low and you're giving away too much of the company. Too high and the equity doesn't feel meaningful to the recipient.
409A valuations. If you're a U.S. company issuing stock options, the IRS requires an independent 409A valuation to set the exercise price. This isn't optional. Companies that skip it or use a stale 409A expose themselves and their employees to serious tax penalties. Most startups need a new 409A annually or after any material event (like a funding round).
M&A conversations. Acquisition interest can surface at any stage. Even preliminary conversations require a shared sense of what the company is worth. Founders who haven't thought about valuation before an acquirer calls tend to either overshoot (killing the conversation) or undershoot (leaving money on the table).
Tax and estate planning. Founders who gift or transfer shares, whether to family members, trusts, or charitable organizations, need a defensible valuation for tax purposes. The IRS can challenge valuations that aren't supported by a recognized methodology.
Each of these situations demands a different level of rigor. A back-of-napkin Berkus Method might be fine for an advisor grant negotiation, but a 409A requires a formal, third-party assessment. Knowing which situation you're in determines how much time and money you should spend on the valuation exercise.
The Berkus Method
Dave Berkus created this method specifically for pre-revenue startups. It assigns up to $500K in value across five risk dimensions: sound idea, working prototype, quality management team, strategic relationships, and product rollout or sales. A company that checks all five boxes tops out at $2.5M pre-money.
The Berkus Method works because it forces both founders and investors to talk about specific risk factors rather than abstract potential. It's best suited for very early companies (Phase 1-2) where there's no traction data to analyze.
Where it breaks down: The $500K caps per category were set years ago and don't adjust for market conditions. A SaaS company in San Francisco and a hardware startup in Des Moines get the same ceiling. It also ignores market size entirely, which means a company addressing a $50M niche scores the same as one addressing a $5B market.
The Scorecard Method
Bill Payne's Scorecard Method (sometimes called the Payne Method) starts with the average pre-money valuation for angel deals in a given region, then adjusts based on weighted factors. The typical factors and weights look like this:
- Team strength: 30%
- Size of opportunity: 25%
- Product/technology: 15%
- Competitive environment: 10%
- Marketing/sales channels: 10%
- Need for additional investment: 5%
- Other factors: 5%
Each factor gets a score relative to the comparison set. If the team is stronger than average, it scores above 100%. If the competitive environment is tougher, it scores below. Multiply each factor's score by its weight, sum them up, and apply that total multiplier to the regional median valuation.
Scorecard Method: A Practical Example
Say the average pre-money valuation for angel deals in your region is $2M. You're evaluating a B2B SaaS company with a strong technical team but no sales leader, targeting a large market with moderate competition.
- Team: 120% x 30% = 0.36
- Opportunity size: 130% x 25% = 0.325
- Product: 100% x 15% = 0.15
- Competition: 90% x 10% = 0.09
- Sales channels: 80% x 10% = 0.08
- Additional investment need: 100% x 5% = 0.05
- Other: 100% x 5% = 0.05
Sum: 1.105
Valuation: $2M x 1.105 = $2.21M pre-money
The Scorecard Method's strength is that it's anchored to real market data (actual deal valuations in your area). Its weakness is that "average pre-money valuation" varies wildly depending on the dataset you're using, and two investors can score the same company very differently on subjective factors like team strength.
Comparable Transactions
This approach values the company by looking at what similar companies raised at similar stages. If three comparable SaaS startups in the same vertical raised seed rounds at $3-5M pre-money, that's your range.
Finding good comparables is the hard part. "Similar" needs to mean similar in stage, market, business model, geography, and timing. A 2021 seed round valuation isn't comparable to a 2024 seed round in the same space because market conditions shifted dramatically between those periods. Evaluating startups on comparables requires knowing what the comparison set actually looked like at the time of funding.
Where it works: Later seed rounds and Series A, where there's enough public and private data to build a meaningful comparison set. Platforms like PitchBook, Crunchbase, and AngelList provide transaction data that makes this method more accessible than it used to be.
Where it breaks down: Very early stage (Phase 1-2) and novel business models where no reasonable comparison set exists.
Cost-to-Duplicate
Cost-to-duplicate calculates what it would cost to rebuild the company from scratch: the technology, the team's time, the patents, the customer relationships, the physical assets. It answers the question, "What's the replacement cost of everything this company has built so far?"
This method appeals to investors who think in terms of tangible value. It's grounded in real expenditures rather than projections. For founders raising their first round, it can set a defensible floor for the negotiation.
Where it breaks down: It ignores future value entirely. A company could have spent $500K building a product that addresses a $2B market with strong early signals, but cost-to-duplicate would still say "$500K." It also can't account for the value of the team's insights, relationships, and domain knowledge, all of which are worth something but can't be tallied on a spreadsheet. Most investors treat this method as a floor, not a ceiling.
Discounted Cash Flow (and Why It's Mostly Useless Pre-Revenue)
DCF models project future cash flows and discount them back to present value using a required rate of return. It's the standard valuation method for established businesses. For pre-revenue startups, it's almost always a waste of time.
Here's why: DCF requires assumptions about future revenue, growth rate, margins, and terminal value. A pre-revenue company has zero data points for any of those inputs. Every number in the model is a guess. Change the growth rate assumption by 5% and the valuation swings by millions. Change the discount rate and it swings again. The output looks precise, but the inputs are fiction.
I've seen founders show up to investor meetings with elaborate DCF models projecting $50M in revenue by year five. The investors flip to the assumptions page, see that everything is built on hypotheticals, and move on. The model didn't build confidence. It undermined it.
When DCF starts to matter: Phase 4-5 companies with 12+ months of revenue data, established unit economics, and enough history to make reasonable forward projections. At that point, the assumptions have a foundation. Before that point, stick with the other methods.
Risk Factor Summation
Risk Factor Summation starts with an average pre-revenue valuation (similar to the Scorecard Method) and then adjusts up or down based on 12 risk categories:
- Management risk
- Stage of the business
- Legislation/political risk
- Manufacturing risk
- Sales and marketing risk
- Funding/capital raising risk
- Competition risk
- Technology risk
- Litigation risk
- International risk
- Reputation risk
- Potential lucrative exit
Each factor gets scored from +2 (very positive) to -2 (very negative), with each point worth roughly $250K. So a company with a net score of +3 across all factors would add $750K to the base valuation.
Risk Factor Summation is the most granular of the pre-revenue methods. It forces a systematic conversation about every category of risk the company faces. For investors running due diligence, the 12 risk factors map well to the areas they're already investigating.
Where it breaks down: The $250K-per-point adjustment is arbitrary and doesn't scale well across markets. Like the Scorecard Method, two investors can score the same company very differently on subjective risk factors.
Valuation Depends on Lifecycle Phase
Gregory Shepard's startup lifecycle framework breaks the startup journey into seven phases, from Vision through Exit. This framework matters for valuation because each phase carries a fundamentally different risk profile, and the appropriate valuation method changes as the company progresses.
At Phase 1-2 (Vision and Build), the Berkus Method and Risk Factor Summation make the most sense because there's nothing to compare and no revenue to model. At Phase 3 (Launch), the Scorecard Method and Comparable Transactions become viable because there's enough substance to benchmark. By Phase 4-5 (Growth and Optimize), DCF and revenue multiples start producing useful outputs because real financial data exists.
The lifecycle phase also determines which investors are appropriate for the round. Early-phase companies match with angels and pre-seed funds who are comfortable with qualitative methods. Later-phase companies match with institutional investors who expect quantitative rigor. Investors who understand lifecycle-aware valuation don't force Phase 2 companies through a Phase 5 evaluation framework.
Picking the Right Method
Don't pick one method and treat it as gospel. The best approach for pre-revenue valuation is triangulation: run two or three methods, compare the outputs, and use the range to frame the negotiation.
If you're a founder preparing for a raise, start with the Scorecard Method (because it's anchored to market data) and the Berkus Method (because it's fast and forces a risk conversation). If comparable deals exist in your space, add those. Present all three to investors and explain your reasoning.
If you're an investor evaluating a pre-revenue company, run Risk Factor Summation alongside whatever the founder presents. It'll surface risk categories that the founder's preferred method might skip. Then verify the company's actual progress against its stage claims, because inflated stage positioning is the fastest way a valuation gets disconnected from reality.
Frequently Asked Questions
What's the best valuation method for a pre-revenue startup?
There's no single best method. The Berkus Method and Scorecard Method are the most commonly used for pre-revenue companies because they're designed for situations where there's no financial data. Running two or three methods and comparing the outputs gives a more reliable range than relying on any single approach.
How do investors value a startup with no revenue?
Most angel investors and early-stage VCs develop a mental model from hundreds of deals, and the formal methods are just scaffolding around that intuition. In practice, team pedigree and market timing often outweigh the scorecard output. An investor who backed a winner in the same vertical will anchor to that outcome. An investor who got burned will discount the same signals. That's why two experienced investors can look at the same company and land on valuations 3x apart. The methods create a shared vocabulary for the negotiation, but the investor's pattern library drives the final number.
Why don't investors use DCF for early-stage startups?
The deeper issue is that DCF gives a false sense of precision. A founder can build a beautiful model showing $30M in year-five revenue, and the math will internally consistent. But the discount rate for a pre-revenue startup should be somewhere between 40% and 70% (reflecting the probability of failure), which crushes the present value of those projections anyway. Experienced investors know that a DCF on a pre-revenue company is really just a set of wishes formatted as a spreadsheet. They'd rather see a Berkus or Scorecard output that's honest about what's knowable and what isn't.
What valuation should a seed-stage startup expect?
Seed-stage valuations vary significantly by market, geography, and sector. In the U.S., pre-money valuations for seed rounds typically range from $2M to $10M, with the median shifting based on market conditions. The specific valuation depends on team strength, market opportunity, product progress, and the competitive dynamics of the fundraise. Anchoring to recent comparable transactions in your sector gives the most realistic expectations.
How does lifecycle stage affect startup valuation?
The practical impact is that your valuation ceiling rises with each phase because you're retiring specific risks. A Phase 1 company carries technology risk, market risk, team risk, and execution risk all at once. By Phase 3, technology and initial market risk are largely resolved, so investors price in fewer failure modes. The jump from Phase 2 to Phase 3 (launching and getting early traction) typically produces the biggest relative valuation increase, often 3x to 5x, because it's the transition from "theory" to "evidence." Founders who understand this can time their fundraise to capture that inflection rather than raising a few months too early.
